

October 13, 2022

BSE Ltd. Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 001

**BSE Scrip Code: 506943** 

Stock Symbol: JBCHEPHARM

Dear Sir,

**Subject: Press Release** 

Enclosed please find press release the Company proposes to issue on Sustainability Report for FY 2021-22 published by the Company.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For J.B. Chemicals & Pharmaceuticals Limited

Sandeep Phadnis
Vice President - Secretarial
& Company Secretary







## **Press Release**

# JB PHARMA PUBLISHES ITS MAIDEN SUSTAINABILITY REPORT

- The sustainability report is for the year FY 2021 2022
- The report is based on the international reporting standards framework, Global Reporting Initiative (GRI) & Sustainable Development Goals (SDGs)
- JB is among few pharmaceutical companies in India to publish its sustainability report

Mumbai, India Oct 13, 2022. J B Chemicals & Pharmaceuticals Ltd (JB Pharma), one of the fastest growing pharma companies in India, today published its inaugural Sustainability (ESG) Report. The report is prepared following the international reporting standards framework, the Global Reporting Initiative (GRI) as its Core Standard, and linkages with the Sustainable Development Goals (SDGs). The report reflects on JB Pharma's commitment to cascading practices across all operations responsible and fostering transparency regarding the company's progress in its ESG objectives. The report can be accessed at www.jbpharma.com

"We are proud to share our inaugural Sustainability report. It is an important step in the right direction and in line with our motto of good health for a healthier world. We believe in conducting business in a socially, environmentally, and ethically responsible manner with a defined approach towards environmental protection, natural resource conservation, and cost efficiency to ensure safety & health protection of our employees, communities, & planet at large." Mentions Nikhil Chopra, CEO, JB Pharma. He further stated that "the company adopted a multi-stakeholder approach to determine its expectations about Environment, Social and Governance issues. The ESG report focuses on key factors which emerged to be most important for our stakeholders during the materiality assessment of our organisation.

Being a responsible company, JB Pharma has been constantly paving the way for enabling a greener and a cleaner word. Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2% and augmented green energy through solar power. Additionally, its Scope 1 and Scope 2 emissions have reduced by 14.6% and 10.7% during the same period.





Through its clean and green initiatives, JB Pharma has also ensured that its waste is properly disposed. During the reporting period, waste sent for co-processing stood at 757.65 MT. All sites are Zero Liquid Discharge. While protecting the environment, the organisation has also ensured protection and well-being of its employees. JB Pharma continuously strives to foster an equitable and desirable work environment through its policies and systems. As a result, the organisation witnessed a 20.6% increase in women workforce across plants from FY 2020 to FY 2022, and 73 female employees working in fields usually dominated by their counterparts in the industry. Its stringent health and safety practices also ensured zero workrelated injuries during the year. With a people-centric approach, its CSR interventions continue to positively impact the lives of thousands across the nation.

#### **About JB Pharma**

J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | ISIN: INE572A01028), established in 1976, is one of the fastest growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has five brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges. The company ranks among the top 5 manufacturers globally in medicated and herbal lozenges. It has seven state of the art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.

For more details on J.B. Pharma, please visit www.jbpharma.com.

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,

CIN: L24390MH1976PLC019380

# **Media Contact**

Dr. Swadeep Srivastava Heal Health PR Tel: +91 93100 87601

Email: drswadeep@hhconnect.in

## **Investor Contact**

Mr. Sidharth Ragnekar / Ms. Shruti Joshi

**CDR India** 

Tel: +91-98335 57572

Email: sidharth@cdr-india.com Shruti@cdr-india.com

